Improving practice . . . Advancing patient care  

Overactive Bladder: AUA/SUFU Clinical Guidelines for Primary Care Physicians


Overactive Bladder: AUA/SUFU Clinical Guidelines for Primary Care Physicians

Topic: Urology
Relevant Terms: Overactive Bladder (OAB)
Primary Audience: Medical Students, Physician Assistants, Primary Care Providers: Primary Care Physicians
Launch Date: 30-Nov-12
Credits: 0.75 AMA PRA Category 1 Credit
1 AAFP CME Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Overactive Bladder for Primary Care Providers

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply the most recent AUA clinical guideline recommendations and best practices to assess and diagnose urological symptoms
  2. Identify and maximize screening opportunities
  3. Skillfully treat and manage urological conditions


    Kathryn L. Burgio, PhD
    Professor of Medicine
    University of Alabama at Birmingham
    Department of Medicine
    Birmingham, AL
    Darryl S. Chutka, MD
    Professor of Medicine
    Mayo Clinic
    Rochester, MN
    Harriette Miles Scarpero, MD
    FellowshipTrained in Female and Pelvic Reconstruction
    St. Thomas Hospital
    Medical Plaza East
    Nashville, TN

    AUA Clinical Guidelines on Overactive Bladder (OAB) for Primary Care Physicians

    Commercial Support Acknowledgement
    Support provided by an educational grant from Astellas Scientific and Medical Affairs, Inc.

    CME Information

    Method of physician participation in the learning process
    1. Read through the CME information.
    2. Click "Enter the Activity" link located at the bottom of the page.
    3. Login. If you do not have an account, you will be prompted to create one. It is recommended that you use your email address for your user name and a password when creating your account.
    4. To claim credit, complete the pre-test, view the webcast, pass the posttest with 80% accuracy and submit the evaluation
    5. Print your certificate for documentation.
    Medium or combination of media used

    Hardware/Software Requirements
    A PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.1 or later, or a Linux computer capable of running Mozilla Firefox 3.0 or later. Processor speed of 800 MHz (1GHz preferred).  A minimum of 128 MB of RAM (more preferred). A modem speed of at least 56k (broadband preferred). Internet browser should be one of the following: Internet Explorer 8.0 or later, Firefox 3.0 or later, Chrome 4.0 or later, or Safari 4.0 or later. Software requirement: Adobe Acrobat Reader 9 or newer.

    Estimated time to complete the educational activity
    0.75 hours

    Statement of Need
    Overactive bladder (OAB), defined as 'urgency, with or without urinary incontinence, usually with frequency and nocturia,' affects 33 million men and women in the United States. Overall, up to 17% of American adults suffer from overactive bladder; yet, only 16% of patients with OAB will receive treatment.
    Primary Care Providers – Front Liners of Screening and Assessment
    Experts recommend primary care as the most appropriate setting for screening, diagnosis and primary treatment of OAB. Although the urologist's crucial role in the health care team must not be discounted, the primary care physician stands at the front line of screening and assessment. In fact, a large percentage of urologic complaints can be successfully diagnosed and managed in the primary care setting, without need for specialist referral. Primary care treatment is often less costly, less time consuming, and less invasive than other settings of treatment. Consequently, patients, physicians, health care providers and health care management systems should make full use of the primary care provider in the assessment and management of overactive bladder (OAB).
    New AUA Clinical Practice Guideline on Overactive Bladder (OAB)
    To ensure consistent, high quality, evidence-based treatment of patients with OAB, the AUA released a Clinical Practice Guideline on Overactive Bladder (OAB) in May 2012. The Guideline focuses on the diagnosis and treatment of OAB and contains useful tools for providers such as a treatment algorithm. The American Board of Urology in conjunction with the AUA continues to emphasize the importance of AUA Guidelines which serve as the basis for clinical diagnostic and treatment formulation.
    Program Purpose and Description
    The purpose of this activity is to provide primary care providers with AUA's new clinical practice guideline on overactive bladder to augment their knowledge of screening methods and identification and treatment options for OAB in the convenience of their office or practice. Special emphasis will be placed on enhanced communication with patients in regards to treatment. Content will be delivered through an educational video based largely on the new AUA guideline on OAB, with content tailored for primary care practitioners. This activity consists of viewing the OAB video and answering a series of questions based on the content of the video.
    The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Credit Designation
    The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    American Academy of Family Physicians (AAFP)
    This Enduring Material activity, AUA Guidelines on Overactive Bladder for Primary Care Providers, has been reviewed and is acceptable for up to 1 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins November 30, 2012. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Evidence Based Content
    It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
    AUA Disclosure Policy
    All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments. 
    Resolution of Identified Conflict of Interest
    All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
    • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
    • Limit content to evidence with no recommendations
    • Introduction of a debate format with an unbiased moderator (point-counterpoint)
    • Inclusion of moderated panel discussion
    • Publication of a parallel or rebuttal article for an article that is felt to be biased
    • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
    Planners and Principal Faculty Credentials and Disclosures
    E. Ann Gormley, MD
    Dartmouth-Hitchcock Med. Ctr.
    1 Medical Center Drive
    Lebanon, NH 
    Disclosures: National Institute of Health – NIDDK
    Kathryn L. Burgio, PhD
    University of Alabama at Birmingham
    Department of Medicine
    Birmingham, AL
    Disclosures:  Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
    Toby C. Chai, MD, FACS
    Professor of Surgery
    Urology Division
    University of Maryland Medical Center
    Baltimore, MD
    Disclosures: Allergan: Consultant or Advisor, Scientific Study or Trial; National Institutes of Health: Scientific Study or Trial; Taris Biomedical: Other; Ion Channel, Inc.: Consultant or Advisor; New England Research Institute: Scientific Study or Trial
    Darryl S. Chutka, MD
    Associate Professor of Medicine
    Mayo Clinic
    Rochester, MN
    Disclosures:  Nothing to disclose
    Deborah J. Lightner, MD
    Mayo Clinic
    Department of Urology
    Rochester, MN
    Disclosures: Nothing to disclose
    Elspeth McDougall, MD, FRCSC, MHPE
    Associate Dean of Continuing Z& Simulation Medical Education
    Director, Minimally Invasive Surgery Education Center
    Chair, AUA Office of Education
    University of California – Irvine
    Irvine, CA
    Disclosures: Ethicon Endo-Surgery: Other; Karl Storz Endoscopy American: Other
    Harriette Miles Scarpero, MD
    St. Thomas Hospital
    Medical Plaza East
    Nashville, TN
    Disclosures: Pfizer, Inc.: Scientific Study or Trial; American Medical Systems (AMS): Consultant or Advisor; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Warner Chilcott: Meeting Participant or Lecturer
    Abid Khan, MHS
    American UrologicalAssociation
    Health Policy:Guidelines
    Linthicum, MD 
    Disclosures:Nothing to disclose

    Off-label or Unapproved Use of Drugs or Devices
    It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
    The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


    © 2012 American Urological Association Education and Research, Inc.®
    Privacy Policy